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Background: Listeriolysin O (LLO) is the main virulence factor of Listeria monocytogenes and facilitates the intracellular
survival of the pathogen. Some of its characteristics endorse the growing popularity of LLO for use in biotechnology,
particularly in the development of novel vaccines. Here, we evaluate the use of LLO to eradicate leukaemia cells.
Results: A purified LLO preparation was obtained by affinity chromatography. The LLO preparation procedure was
optimized and purified LLO was tested for optimal conditions of storage including temperature, application of
proteinase inhibitors and serum components. We demonstrated the possibility of regulating LLO activity by adjusting
cell membrane cholesterol content. The LLO preparation had haemolytic activity and had a cytotoxic effect on the
human T-leukaemia Jurkat cell line as well as mouse and human peripheral blood mononuclear cells.
Conclusions: LLO has a very potent cytotoxic activity towards human leukocytes. Importantly, the cytotoxic activity
was easily regulated in vitro and could be restricted to areas containing malignant cells, raising the possibility of future
clinical application of LLO for leukaemia treatment.
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Most bacterial pathogens produce toxins, which are im-
portant virulence factors. Some toxins act on cytoplas-
mic membranes, whereas others are receptor-targeted
toxins or membrane damaging toxins. The latter toxins
are referred to as cytolysins, and are produced by numer-
ous Gram-positive and Gram-negative bacteria. Some of
these toxins display enzymatic activity, while others have
cytolytic capacity without enzymatic activity. Occasionally
those two mechanisms may act together. For example
some phospholipases facilitate the action of pore-forming
cytolysins by hydrolysing membrane lipids [1].
Pore-forming cytolysins are a class of membrane-
damaging toxins without enzymatic activity. They act by
the insertion of their hydrophobic regions into the cell
membrane phospholipid bilayer, effectively disrupting the
target cells. The most homogenous and numerous group
of membrane pore-forming cytolysins are Cholesterol
Dependent Cytolysins (CDC). CDCs are produced mostly* Correspondence: jkawiak@cmkp.edu.pl
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article, unless otherwise stated.by Gram-positive bacteria and share similar amino acid
sequences and biochemical properties [2]. Listeria mono-
cytogenes is an intracellular bacterial pathogen whose im-
portant virulence determinants are secreted toxins, one of
which is listeriolysin O (LLO), a cytolysin encoded by the
hly gene belonging to the CDC family. This protein is cru-
cial for pathogen survival within the cytoplasm of the in-
fected cell [3,4].
There have been several attempts to develop effective
LLO purification methods using recombinant Escherichia
coli strains [5-9]. Previously, we attempted to use modified
bacteria species enclosed within capillary membranes
using in vitro experiments with human T leukaemia Jurkat
cells [10]. Here we present an improved LLO purification
protocol and the results of in vitro experiments to deter-
mine the haemolytic and cytotoxic activity of purified
LLO on peripheral blood leukocytes. The concentration-
dependent activity of purified LLO was tested on a human
T cell leukaemia cell line (Jurkat) and on normal per-
ipheral blood mononuclear cells (PBMC). This study
might provide useful information for future in vivo test-
ing of LLO.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Purification of Listeriolysin O
The synthesis and affinity purification of His-tagged
LLO from E. coli harbouring a pET29b-hly plasmid was
optimized with a set of buffers with the following gradi-
ent: buffer pH ranging from 5 to 8 and NaCl concentra-
tion from 0 to 0.5 M. The concentration of imidazole
ranged from 0 to 100 mM (for the column buffer) and
from 0.25 to 1 M (for the elution buffer). Final protocol
and optimal buffer composition are described in the
Methods. Notably, lowering the pH of the elution buffer
from 8 to 6 allowed a four-fold reduction of the imidazole
concentration without a detectable loss of efficiency as
compared to the original elution buffer (1 M imidazole,
pH 8). The analysis of electrophoretically separated E. coli
lysates and purified LLO preparation was performed.
The results of SDS-PAGE for LLO purified fractions
and western blotting results with anti-LLO antibodies
are presented in Figure 1. Total protein electrophoresis
(Figure 1A) of E. coli sonicate (lane 1), purified LLO
preparation (lane 2), and western blotting of purified
LLO preparation with anti-LLO antibodies (right B 1Figure 1 Electrophoresis analysis of LLO samples. Total protein
(1), electrophoresis (A), and western blot (B). The purified LLO
preparation (2) shows one band similar to immunochemical reaction
with anti-LLO antibodies.and 2 lanes) suggested the presence of a highly uniform
protein preparation.
The presence of a single protein of approximately
58 kDa, equivalent to the LLO molecular mass was ob-
served. The cytotoxic potential of the purified LLO
preparation, prior to application on a Jurkat cell line,
was tested on SRBC (sheep red blood cells) for haemo-
lytic activity assay. For most experiments preparations
were standardized as follows: the LLO concentration
was set at 1.5 μg/ml and samples (3000 HU/ml) were
stored at −70°C. To facilitate its application, conditions
for longer storage were optimized. The following com-
pounds at various concentrations were tested: glycerol
(from 0 to 20%), buffer pH (from 5 to 8), cysteine (from
0 to 10 mM), EDTA (0 to 20 mM) and AEBSF - fluoro
4-(2-aminoethylo)-benzenesulphonyl.HCl (0 to 2 mM).
The results for the effects of glycerol and pH on LLO
stability are presented in Figures 2 and 3, respectively.
The most potent concentration of glycerol (15%) and
pH value (6) were used for all further experiments. For
the remaining reagents tested, the differences in their
ability to preserve LLO activity were less distinguishable
(data not shown). However, the presence of protease in-
hibitors was necessary to preserve optimum LLO activ-
ity. We concluded that the following conditions for LLO
preparation storage were optimal for the purified LLO
preparation: 1 mM AEBSF, 10 mM EDTA, 15% glycerol,
5 mM cysteine-HCl, pH 6 and a temperature of −70°C.
We observed that even after several months of storage,
LLO samples retained significant activity.
Cytotoxic activity
The cytotoxicity of the purified LLO preparation was
tested on a Jurkat cell line at 22°C and 37°C (Figure 4). The
cytotoxic activity of LLO was concentration-dependent
and was similar at both temperatures under the test condi-
tions employed. Storage of the LLO preparation even
in the presence of protease inhibitors and 10% glycerol
at −70°C significantly decreased the preparation activ-
ity (p < 0.0001) (Figure 5). However, even the addition
of 3% glycerol stored purified LLO preparation killed
50% of Jurkat cells and the presence of 30% glycerol
purified LLO preparation killed 95% of the cells.
LLO activity in culture medium containing cholesterol
The cholesterol dependency of LLO was tested. The
cytotoxicity of the LLO preparation was tested on Jurkat
cell line in NCS (neonatal calf serum) medium contain-
ing cholesterol (390 μM) (Figure 6). The results showed
significant inhibition (p < 0.0001) of the killing properties
of purified LLO in medium composed of serum contain-
ing cholesterol.
The dependence of LLO activity on cholesterol is well
known. Cholesterol in cell membranes is assumed to act
Figure 2 Effect of glycerol concentrations on LLO stability. LLO samples were supplemented with varying GOL concentrations (0–20%) and
frozen. The haemolytic activity was checked regularly at 5 days intervals.
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cholesterol content within cell membranes may be in-
hibitory. Similarly, the presence of cholesterol in incuba-
tion medium may bind to LLO, which in turn may
prevent its binding to cell membranes. The cell mem-
brane cholesterol content may be diminished by the
addition of methyl-β-cyclodextrin (MβCD) to culture
medium. This was tested by preincubation of Jurkat cells
for 1 h at 37°C in RPMI1640 containing 26 μM choles-
terol or 5 mM MβCD or both of these compounds. The
effect of these reagents on membrane cholesterol con-
tent was verified by cholesterol assay. As anticipated, the
addition of cholesterol increased its membrane content
while incubation with MβCD completely removed chol-
esterol from cellular membranes (Figure 7).
Jurkat cells preincubated with modified cholesterol
content were subsequently incubated with purified LLO
for 30 min the survival rate of the cells was assessed
(Figure 8).
The cholesterol concentration dependence on LLO
was compared with RPMI1640, and RPMI1640 contain-
ing 26 μM cholesterol or 5 mM of MβCD. StatisticallyFigure 3 Effect of pH on LLO stability. LLO samples were set to differen
checked regularly at 5 days intervals.significant (p < 0.004) differences were noted between
cholesterol or MβCD samples and the controls. Interest-
ingly, in medium containing 5% LLO and cholesterol, up
to 54% of Jurkat cells survived. A similar percentage of cell
survival (51.5%) was observed in the presence of MβCD in
the medium as compared with control medium where
only 2% of Jurkat cells survived. When both factors were
present almost all cells survived, and the cytotoxic activity
of LLO was completely blocked. Here the MβCD molar
concentration was about 200 times higher than the chol-
esterol concentration.
Sensitivity of human and mouse PBMC to the purified
LLO preparation
Human or mouse PBMC were isolated, diluted to a con-
centration of 1 × 106 cells/ml, incubated in RPMI 1640-
10% NCS with protease inhibitors and their survival rate
tested after incubation with the purified LLO prepar-
ation. Concentration dependence survival was observed
(Figure 9) in a cytometric test with propidium iodide
(PI). Statistically significant differences for human and
mouse PBMC sensitivity to LLO was observed (p < 0.005).t pH values (from 5 to 8) and frozen. The haemolytic activity was
Figure 4 Activity of purified LLO on Jurkat cell line. LLO concentration dependence, temperature dependence and conditions of storage
were compared. Presented values show the percentage of living cells after exposure to LLO. Cytotoxicity of LLO at 22°C and 37°C were compared
on preparations without protease inhibitors, and the influence of storage for 25 days (at −70°C) of LLO preparations on cytotoxicity in the presence of
protease inhibitors was assessed. FP –freshly prepared LLO preparation; ST- stored LLO preparation. Median values; P25 and P75, n = 3, p < 0.0001
between FP and ST. Differences in cytotoxic activity at 22°C and 37°C were not significant.
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purified LLO concentration 54% of mouse PBMC sur-
vived, in contrast to only 14% of human cells.
Discussion
In this study, an E. coli strain expressing his-tagged LLO
was used, similar to previous reports. However, in con-
trast to those studies, which used standard elution buffer
(pH 8) with one exception [7], here we proposed a
modified procedure for LLO purification. To the best of
our knowledge, this is the first application of an acidic
buffer for the purification of LLO with nickel - nitrilo-
triacetic acid (Ni-NTA) resin. The use of low pH bufferFigure 5 LLO stability in the presence of protease inhibitors tested on
inactivated NCS. Presented values show percentage of living cells after ex
with controls without inhibitors.offers two advantages over commonly used pH 8 elution
buffer: (i) it effectively reduces the ability of Ni-NTA
resin to bind proteins, facilitating the elution of a higher
protein yield with lower imidazole concentrations, and
(ii) it preserves the activity of the LLO protein. Given
that all CDCs share similar biochemical features and
have a similar overall structure [2], the purification
method described here should be applicable for other
CDCs. Storage conditions are, however, most likely re-
stricted to Listerial cytolysin due to its unique character-
istics [3,4]. The storage conditions that promoted the
stability of LLO haemolytic activity and cytotoxic activity
were confirmed using sheep erythrocytes and JurkatJurkat cells incubated in RPMI 1640 medium containing 4%
posure to LLO. Median value, P25 and P75, n = 3, p < 0.0001 compared
Figure 6 Effect of serum containing cholesterol on LLO cytotoxicity. Cytotoxicity assay on a Jurkat cell line in RPMI-1640 without NCS and in
100% inactivated NCS with PI. NCS contained 390 μM (150 mg/dl) of cholesterol. Results show percentage of living cells. LLO concentration
dependence was compared. Median values; P25 and P75, n = 4, p < 0.0001.
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ase inhibitors on the stability of the purified LLO prep-
aration suggested the presence of active proteases in the
purified preparation of LLO.
It was shown that purified LLO demonstrates the
properties of an authentic Listeria monocytogenes pro-
tein. Listeriolysin O is crucial for pathogen survival
within the cytoplasm of infected cells [3,4]. Less well
known is the activity dependence of purified LLO when
applied outside the cell, on the cell membrane. The cell
membrane might not be as uniform as predicted by the
classical fluid mosaic model, and could contain differ-
ently arranged regions. The lipid raft hypothesis de-
scribes membrane areas stabilized by cholesterol within
a liquid-ordered phase. These areas are engaged in the
regulation of cell adhesion, transport, sorting of lipids
and proteins and signal transduction. Membrane lipidFigure 7 Cholesterol content in Jurkat cells after cholesterol and MβC
containing 26 μM cholesterol or 5 mM MβCD or both these compounds. Rrafts are regions where cholesterol and marker proteins
such as CD59 are concentrated [11,12]. While choles-
terol acts as a receptor for all CDCs, CD59 is considered
an additional receptor for two CDC toxins [13]. Possibly,
other CDCs also require additional factors, which might
explain some long-observed differences in different cells
susceptibility to CDCs activity. Human leukocytes were
significantly more sensitive than mouse cells to LLO ac-
tivity. This might be simply a result of the different over-
all sensitivity of human and mouse cells or a specific
difference between cellular receptors, possibly lipid rafts.
Very subtle differences at the molecular level might be
of great importance, i.e. the difference of a single amino
acid for Internalin (Inl) A–E-cadherin interactions. Hu-
man cadherin is preferentially targeted by the InlA sur-
face protein [14]. L. monocytogenes is better adopted to
infect humans than mice and might explain its highD treatment. Jurkat cells were incubated for 1 h at 37°C in RPMI1640
esults show cholesterol content in μg per 106 cells.
Figure 8 Effect of cholesterol and MβCD pre-treatment on Jurkat cells survival. Jurkat cells were preincubated in RPMI 1640 for 1 h at 37°C
with cholesterol (26 μM; 10 μg/ml) or MβCD (5 mM) or a mixture of both. Then LLO was added and the sample was incubated for 30 min. LLO
cytotoxicity was tested on a Jurkat cell line with PI. Values represent percentage of living cells. LLO concentration dependence was compared.
Median values; P25 and P75, n = 4 p < 0.004 between control and cholesterol or MβCD groups.
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L. monocytogenes survival in human cells.
The cytotoxic activity of purified LLO was observed
when applied to human leukocytes in the presence of a
known concentration of cholesterol and/or MβCD in the
medium, which removed cholesterol from cell mem-
branes. We concluded that the presence of cholesterol
in cell membranes and in the culture medium modified
the cytotoxic activity of purified LLO. During in vivo
conditions, the presence of cholesterol is expected in
peripheral blood plasma; however, it may also be present
within the tissue matrix [15]. The LLO preparation may
have application when locally administered directly into
tissues, e.g. subcutaneously, intraperitoneally, intraorgan-
ally or intratumourally. We demonstrated the possibilityFigure 9 Comparison of human and mouse PBMC sensitivity to LLO c
mouse PBMC (1 × 106/ml) in RPMI 1640 containing 4% NCS with PI. The pe
compared. Median values; P25 and P75, n = 3, p < 0.005.of simple regulation of LLO cytotoxic activity in vitro by
the additional application of cholesterol or MβCD. This
might also have practical significance in vivo although the
safety of such a treatment might be an issue. However, it
might be possible since cyclodextrins are already in clin-
ical use [16]. The LLO preparation has haemolytic activity
and cannot be applied intravenously; however its intraper-
itoneal or subcutaneous application is possible. The rela-
tively low activity and stability of LLO in physiological
conditions should be advantageous and allow the restric-
tion of cytotoxic activity to selected regions, thus limiting
possible side-effects. However, the specificity of cytotoxin-
based anti-cancer therapy remains a great challenge. This
could be resolved by combining toxic components with
antibodies, producing so called immunotoxins. The mostytotoxicity. Results of purified LLO cytotoxicity tested on human and
rcentage of living cells is shown. LLO concentration dependence was
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exotoxin A derived from Pseudomonas aeruginosa and
diphtheria toxin from Corynebacterium diphtheriae [17,18].
Although its mode of action might appear to preclude
the combination of CDCs with antibodies, it was re-
cently shown that directing cytotoxicity using antibodies
is applicable for LLO [19]. The cytotoxic features of LLO
and the possibility of controlling its activity make it a good
immunotoxin candidate, although the direct use of
LLO for clinical treatment must be preceded by a de-
tailed description of its activity under the form of puri-
fied preparation.
Conclusions
In this study, we purified LLO by affinity chromatog-
raphy demonstrating the usefulness of acidic buffer to
remove LLO from Ni-NTA resin. The satisfactory stor-
age conditions of the purified LLO preparation were also
demonstrated to be an important step before planning
use of the toxin. This study underscores the role of cryo-
preservative glycerol and a thiol-reducing agent, cyst-
eine, for LLO stability and activity. The storage additives
in the doses used were not toxic to eukaryotic cells,
while LLO displayed potent in vitro activity towards leu-
kaemia cells. LLO activity was easily regulated in vitro
and possibly in vivo, and this information might facilitate
its future clinical application.
Methods
Escherichia coli strains and growth conditions
The source of purified LLO was E. coli strain BL21(DE3)
(Novagen, Madison, Wis) with plasmid pET29B (Novagen)
carrying cloned hly gene, kindly provided by Dr. Higgins
[6]. The bacteria were grown in LB broth (Sterbios, Warsaw,
Poland), supplemented with 30 μg/ml kanamycin (Merck,
Darmstadt, Germany) at 37°C with 120 rpm shaking. Bac-
teria were cultured until the optical density reached 1.5.
To induce LLO-His synthesis, IPTG (Sigma, Taufkirchen,
Germany) was added to a final concentration of 1 mM.
Eukaryotic cell isolation and growth conditions
The target Eukaryotic cells were: SRBC - sheep red
blood cells (Biomed, Warsaw, Poland), human acute T
cell leukaemia cell line (Jurkat, ATCC TIB 152), and
PBMC isolated from humans or mice.
Jurkat cells were grown in RPMI 1640 culture medium
(Gibco, Gaithersburg, MD, USA) with 10% of inactivated
NCS containing 100 U of penicillin and 0.1 mg of strepto-
mycin per 1 ml or in DMEM medium (Sigma) with 10% of
inactivated NCS. Serum contained 150 mg/dl cholesterol,
and the final cholesterol concentration in the culture
medium was 15 μg/ml (39 μM).
PBMC were cultured, after isolation, in vitro for 2–7 days
before a cytotoxicity experiment. For human peripheralblood experiments in vitro, patients gave their personal
consent and the procedure was accepted by the Bioethical
Commission at the Medical Center of Postgraduate Educa-
tion, Warsaw (Feb 27, 2008).
Isolation of PBMC was performed by an overlayer of
peripheral blood diluted with PBS (1:1), on 5 ml of His-
topaque 1077 (Sigma) preparation in a test tube and
centrifugation for 30 min at 540 × g. The interlayer of
PBMCs consisting of lymphocytes and monocytes was
separated and diluted with 10 ml of culture medium,
centrifuged for 5 min at 200 × g and the washed cells
suspended in fresh culture medium were counted in a
Burker camera. The concentration of the cell suspension
was corrected to a final value of 2 × 106/ml before cul-
turing. The cultures were performed in Falcon vessels
(dishes) or in 6-well flat bottom plates in RPMI 1640
with 10% NCS and antibiotics, and half of the medium
volume was changed twice weekly.
For some experiments cell cultures were supplemented
with the following compounds to modify the LLO activ-
ity: cholesterol (Sigma), NCS containing 150 μg/ml chol-
esterol (390 μM), and MβCD (Sigma).
The affinity chromatography of LLO
Ten ml of E. coli suspension (approximately 108/ml)
grown in the presence of 1 mM IPTG was centrifuged at
4400 × g for 10 min at 4°C, and the supernatant was re-
moved. The pelleted cells were resuspended in 1 ml of
sterile column buffer (50 mM Tris, pH 8, 300 mM NaCl,
50 mM imidazole) and were ruptured by sonication in 3
pulses of 30 s each. Then, the bacterial fragments were re-
moved by centrifugation (7000 × g, 15 min). The super-
natant was collected, diluted with column buffer and
applied onto the affinity column (His-Bind Ni Column,
Novagen) previously equilibrated with the column buffer.
The column was washed with the same buffer, and then
LLO was desorbed with the elution buffer (50 mM MES,
pH 6, 300 mM NaCl, 250 mM imidazole). The collected
fraction was subsequently dialysed to remove imidazole
(50 mM MES, pH 6, 300 mM NaCl, 5 mM cysteine HCl).
Protease inhibitors: fluoro 4-(2-aminoethylo)-benzenesul-
phonyl.HCl (AEBSF, Sigma), EDTA (Sigma), and glycerol
(Merck) were added to a final concentration of 1 mM,
10 mM, and 15% (v/v), respectively. Protein concentra-
tions were assayed with NanoOrange® Protein Quantita-
tion Kit (Molecular Probes) using an infinite M200 PRO
reader (TECAN, Goring on Thames, UK).
Western blot analysis of LLO preparations
Electrophoretically resolved proteins (SDS-PAGE) were
transferred onto a nitrocellulose membrane using the
BIO-RAD Trans-Blot system, according to a protocol
recommended by the manufacturer. The membrane was
blocked using 5% skimmed milk in Tris-buffered saline
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antibody (Abcam, Cambridge, MA, USA) and secondary
goat polyclonal antibody (Abcam) conjugated with alka-
line phosphatase were used at 1:1500 and 1:10,000 dilu-
tions, respectively. The membrane was developed using
the NBT/BCIP reagent (Merck).
Assay of haemolytic activity
Haemolytic activity was assayed using SRBC. The eryth-
rocytes were washed three times with PBS and sus-
pended to a final concentration of 20% (v/v) in PBS
(pH 7.4). The LLO preparation was diluted by adding
10 μl of its preparation to a final volume of 1 ml of 2%
SRBC suspension in PBS. The prepared solution was in-
cubated for 30 min at 37°C and then centrifuged for
3 min at 150 × g. The released haemoglobin was mea-
sured spectrophotometrically at λ = 410 nm. Haemolytic
Units (HU) were calculated after setting 0 HU as the ac-
tivity of a negative control, and 100 HU for total haem-
olysis, observed in samples of erythrocytes lysed with
0.01% SDS.
Cholesterol assay
Jurkat cells were resuspended in fresh RPMI medium
without any additives (control), supplemented with 26 μM
cholesterol, with 5 mM MβCD or with both these com-
pounds. The cells were incubated for 1 h at 37°C, washed
with PBS three times, counted and disrupted by sonic-
ation. Membrane cholesterol was extracted with isopropa-
nol and quantified by a cholesterol assay kit (R-Biopharm,
Darmstadt, Germany).
Cytometric assays
The activities of the LLO preparations were tested on
Jurkat cells or PBMC. The Jurkat cell suspension in a
culture medium (1 × 106/ml) of 20 μl, was mixed with
30 μl of LLO preparation diluted with physiological salt
solution at different proportions, and immediately incu-
bated for 30 min at room temperature (20–22°C). The
time of the incubation was assumed to be the same as
for the haemolytic assays. The final cell concentration
was 0.4 × 106/ml. The effect of the LLO preparation was
titrated in an assay volume of 50 μl containing cell sus-
pension (20 μl) and 30 μl of physiological salt solution
containing the LLO preparation. The LLO preparation
content investigated was: 0.5, 1, 2, 3, 4, 5, 10, 20, 30, 40,
and 50% of the original LLO concentration (1.5 ng/μl)
with activity set at 3 HU/μl. After cell sample incuba-
tion, physiological saline containing PI (1 μg/ml) was
added before acquisition by a cytometer. PI penetrates
the cell membrane of damaged cells and binds to the cell
nucleus. In the fluorescence quadrant readings of forward
scatter (FSC)/PI fluorescence, the PI unstained events in-
dicate the percentage of living cells. In the FACSCaliburBD cytometer, 5000 events were collected from each
sample and analysed by Cell Quest software (Becton
Dickinson, Franklin Lakes, NJ, US). Experiments were
repeated at least three times.
Statistical analysis
The flow cytometry results were presented as median
values and percentile values P25 and P75. Statistical ana-
lysis of flow cytometric experiments was in the global
linear model (GLM) after logit transformation of values.
The post hoc test of Tukey was used. Results of haemo-
lytic assays were presented as mean values ± standard
deviation (SD). Analysis of variance was performed by
ANOVA. Statistically significant values of p < 0.05 were
assumed. Statistical software SAS 9.2 was used.
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